https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer
Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
https://www.facingourrisk.org/research-clinical-trials/study/303/social-support-and-coping-strategies-among-lgbtqia-cancer-patients
Surveys, Registries, Interviews
This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients
https://www.facingourrisk.org/research-clinical-trials/study/149/promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness
Clinicaltrials.gov identifier:
NCT04995198 (https://clinicaltrials.gov/show/NCT04995198)
Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study
Clinicaltrials.gov identifier:
NCT04711109 (https://clinicaltrials.gov/show/NCT04711109)
Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
This study will examine how Olaparib in combination with the drugs Cediranib or Ceralasertib works for patients with advanced breast cancer who have BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5
Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)
Prevention
Screening study for people at high risk for pancreatic cancer
https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)
Prevention
Screening study for people with a mutation linked to prostate cancer risk
https://www.facingourrisk.org/research-clinical-trials/study/313/mastectomy-decision-support-study
Surveys, Registries, Interviews
Interviews with women who underwent a bilateral mastectomy to receive feedback on educational materials
https://www.facingourrisk.org/research-clinical-trials/study/315/a-study-on-ethical-challenges-in-genetic-testing-for-terminally-ill-patients-and-their-families
Surveys, Registries, Interviews
Interview of palliative care patients and/or their adult family members who have been offered and involved in genetic testing or counseling
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Clinicaltrials.gov identifier:
NCT04673448 (https://clinicaltrials.gov/show/NCT04673448)
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
https://www.facingourrisk.org/research-clinical-trials/study/306/the-detect-study-detecting-endometrial-cancer-in-tampons
Clinicaltrials.gov identifier:
NCT03538665 (https://clinicaltrials.gov/show/NCT03538665)
Prevention
Early detection of endometrial cancer in women over 45 years of age who are undergoing hysterectomy surgery at the University of Alabama
https://www.facingourrisk.org/research-clinical-trials/study/273/testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05419011 (https://clinicaltrials.gov/show/NCT05419011)
Prevention
Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/309/uplift-cancer-caregivers-study
Surveys, Registries, Interviews
Survey to understand the impact of caregiving on the mental, physical, and financial well-being of LGBTQ+ people providing unpaid care to a family or friend with cancer
https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05646316 (https://clinicaltrials.gov/show/NCT05646316)
Treatment
People with stage I endometrial cancer who are having a hysterectomy
https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u
Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/307/the-lift-up-study
Clinicaltrials.gov identifier:
NCT04541654 (https://clinicaltrials.gov/show/NCT04541654)
Surveys, Registries, Interviews
Study looking at cancer risk for people with Li-Fraumeni syndrome
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Clinicaltrials.gov identifier:
NCT06022029 (https://clinicaltrials.gov/show/NCT06022029)
Treatment
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/301/registry-to-discover-new-treatments-and-developmental-processes-of-colorectal-and-endometrial-cancer-in-patients-with-hereditary-cancer
Clinicaltrials.gov identifier:
NCT06096688 (https://clinicaltrials.gov/show/NCT06096688)
Surveys, Registries, Interviews
Study to collect and save data, cancer samples, and cancer family health histories from people who screen for colorectal endometrial cancer
https://www.facingourrisk.org/research-clinical-trials/study/299/the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer
Clinicaltrials.gov identifier:
NCT05961709 (https://clinicaltrials.gov/show/NCT05961709)
Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR
https://www.facingourrisk.org/research-clinical-trials/study/295/shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry
Clinicaltrials.gov identifier:
NCT05654246 (https://clinicaltrials.gov/show/NCT05654246)
Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/120/the-risk-factor-analysis-of-hereditary-breast-and-ovarian-cancer-in-women-with-brca1-brca2-or-palb2-mutations
Surveys, Registries, Interviews
https://www.facingourrisk.org/research-clinical-trials/study/285/treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.
https://www.facingourrisk.org/research-clinical-trials/study/308/study-of-the-drug-sovilnesib-in-people-with-ovarian-cancer
Clinicaltrials.gov identifier:
NCT06084416 (https://clinicaltrials.gov/show/NCT06084416)
Treatment
Treatment study for people with platinum-resistant ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/119/a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation
Surveys, Registries, Interviews
https://www.facingourrisk.org/research-clinical-trials/study/294/high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation
Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/302/roadmap-to-parenthood-a-study-about-fertility-and-family-building-after-cancer
Clinicaltrials.gov identifier:
NCT06050135 (https://clinicaltrials.gov/show/NCT06050135)
Surveys, Registries, Interviews
Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
https://www.facingourrisk.org/research-clinical-trials/study/286/swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation
Clinicaltrials.gov identifier:
NCT05806515 (https://clinicaltrials.gov/show/NCT05806515)
Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT05572684 (https://clinicaltrials.gov/show/NCT05572684)
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation
Clinicaltrials.gov identifier:
NCT06005974 (https://clinicaltrials.gov/show/NCT06005974)
Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation
https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment
Clinicaltrials.gov identifier:
NCT05217446 (https://clinicaltrials.gov/show/NCT05217446)
Treatment
Study for metastatic colorectal cancer that has not yet been treated
https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap
Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)
Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery
https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer
Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
https://www.facingourrisk.org/research-clinical-trials/study/275/exploring-how-people-of-caribbean-descent-share-information-about-their-genetic-mutations-with-their-family-members
Surveys, Registries, Interviews
Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.
https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting
Clinicaltrials.gov identifier:
NCT05253651 (https://clinicaltrials.gov/show/NCT05253651)
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.
https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk
Clinicaltrials.gov identifier:
NCT04970056 (https://clinicaltrials.gov/show/NCT04970056)
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
https://www.facingourrisk.org/research-clinical-trials/study/199/young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors
Clinicaltrials.gov identifier:
NCT04906200 (https://clinicaltrials.gov/show/NCT04906200)
Quality of Life
Women diagnosed with breast cancer between the ages of 15-39
https://www.facingourrisk.org/research-clinical-trials/study/256/early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05410977 (https://clinicaltrials.gov/show/NCT05410977)
Prevention
People with Lynch Syndrome at risk for colon cancer
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study
Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)
Prevention
Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule
https://www.facingourrisk.org/research-clinical-trials/study/270/living-well-a-web-based-program-to-improve-quality-of-life-in-ovarian-cancer-survivors
Clinicaltrials.gov identifier:
NCT04533763 (https://clinicaltrials.gov/show/NCT04533763)
Quality of Life
A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors.
https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer
Clinicaltrials.gov identifier:
NCT05608694 (https://clinicaltrials.gov/show/NCT05608694)
Prevention
Screening using MRI for men at risk of developing prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/258/my-best-gi-eating-study
Clinicaltrials.gov identifier:
NCT05396846 (https://clinicaltrials.gov/show/NCT05396846)
Prevention
Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer
https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
https://www.facingourrisk.org/research-clinical-trials/study/277/registry-to-promote-health-equity-for-people-of-african-ancestry-with-breast-or-prostate-cancer
Clinicaltrials.gov identifier:
NCT05754658 (https://clinicaltrials.gov/show/NCT05754658)
Surveys, Registries, Interviews
This is a registry for people of African ancestry who have breast or prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)
Prevention
Prevention study for women at high risk for ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/272/quality-of-life-study-for-caregivers-involving-in-person-or-telephone-coaching-sessions
Clinicaltrials.gov identifier:
NCT04318886 (https://clinicaltrials.gov/show/NCT04318886)
Quality of Life
Quality of life study for caregivers involving in-person or telephone coaching sessions
https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis
Clinicaltrials.gov identifier:
NCT05223036 (https://clinicaltrials.gov/show/NCT05223036)
Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04367675 (https://clinicaltrials.gov/show/NCT04367675)
Prevention
People with a BRCA1 or BRCA2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/280/survey-about-goals-of-inherited-cancer-risk-disclosure-in-families-with-an-inherited-gene-mutation
Surveys, Registries, Interviews
Survey for people with an inherited gene mutation
https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)
Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.
https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05411718 (https://clinicaltrials.gov/show/NCT05411718)
Prevention
Prevention study for people with Lynch syndrome
https://www.facingourrisk.org/research-clinical-trials/study/255/kindred
Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation
https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT02628067 (https://clinicaltrials.gov/show/NCT02628067)
Treatment
Treatment study for people with advanced cancers
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)
Treatment
Cancer treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
https://www.facingourrisk.org/research-clinical-trials/study/240/metastatic-castration-resistant-prostate-cancer-clinical-trial
Clinicaltrials.gov identifier:
NCT03460977 (https://clinicaltrials.gov/show/NCT03460977)
Treatment
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.
https://www.facingourrisk.org/research-clinical-trials/study/238/survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening
Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.
https://www.facingourrisk.org/research-clinical-trials/study/175/niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects
Clinicaltrials.gov identifier:
NCT04030559 (https://clinicaltrials.gov/show/NCT04030559)
Treatment
High-risk localized prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/228/opening-the-conversation
Clinicaltrials.gov identifier:
NCT04806724 (https://clinicaltrials.gov/show/NCT04806724)
Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)
Treatment
Treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/226/survey-for-people-diagnosed-with-breast-cancer-to-provide-feedback-on-a-new-type-of-clinical-trial
Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/219/effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer
Clinicaltrials.gov identifier:
NCT04837820 (https://clinicaltrials.gov/show/NCT04837820)
Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction
Clinicaltrials.gov identifier:
NCT04533373 (https://clinicaltrials.gov/show/NCT04533373)
Prevention
Study for people undergoing DIEP flap reconstruction
https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04858334 (https://clinicaltrials.gov/show/NCT04858334)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors
Clinicaltrials.gov identifier:
NCT05056077 (https://clinicaltrials.gov/show/NCT05056077)
Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer
https://www.facingourrisk.org/research-clinical-trials/study/223/factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer
Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)
Prevention
People at high risk for prostate cancer due to an inherited mutation
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05252390 (https://clinicaltrials.gov/show/NCT05252390)
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/220/physical-activity-at-home-for-relief-from-neuropathy-caused-by-taxanes-in-people-with-breast-cancer
Clinicaltrials.gov identifier:
NCT04621721 (https://clinicaltrials.gov/show/NCT04621721)
Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy
https://www.facingourrisk.org/research-clinical-trials/study/210/treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra
Clinicaltrials.gov identifier:
NCT04038502 (https://clinicaltrials.gov/show/NCT04038502)
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer
Clinicaltrials.gov identifier:
NCT03568630 (https://clinicaltrials.gov/show/NCT03568630)
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Clinicaltrials.gov identifier:
NCT05483283 (https://clinicaltrials.gov/show/NCT05483283)
Prevention
Latinas with a high risk of breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening
Clinicaltrials.gov identifier:
NCT03474913 (https://clinicaltrials.gov/show/NCT03474913)
Prevention
Screening for prostate cancer using upright MRI
https://www.facingourrisk.org/research-clinical-trials/study/218/bazedoxifene-plus-conjugated-estrogens-for-hot-flashes-in-women-at-high-risk-for-breast-cancer
Clinicaltrials.gov identifier:
NCT04821141 (https://clinicaltrials.gov/show/NCT04821141)
Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes
https://www.facingourrisk.org/research-clinical-trials/study/207/research-opportunity-for-previvors-and-their-romantic-partners
Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners
https://www.facingourrisk.org/research-clinical-trials/study/169/brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences
Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing
https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Clinicaltrials.gov identifier:
NCT04150042 (https://clinicaltrials.gov/show/NCT04150042)
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Clinicaltrials.gov identifier:
NCT05677048 (https://clinicaltrials.gov/show/NCT05677048)
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
https://www.facingourrisk.org/research-clinical-trials/study/197/all-of-us-research-program
Surveys, Registries, Interviews
Anyone age 18 or over
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04584255 (https://clinicaltrials.gov/show/NCT04584255)
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
https://www.facingourrisk.org/research-clinical-trials/study/195/inherited-cancer-registry-icare-contribute-to-research-while-staying-informed
Clinicaltrials.gov identifier:
NCT03231891 (https://clinicaltrials.gov/show/NCT03231891)
Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family
https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation
Clinicaltrials.gov identifier:
NCT04548752 (https://clinicaltrials.gov/show/NCT04548752)
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)
Treatment
Advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Clinicaltrials.gov identifier:
NCT03607890 (https://clinicaltrials.gov/show/NCT03607890)
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
https://www.facingourrisk.org/research-clinical-trials/study/137/developing-a-test-for-the-detection-of-ovarian-cancer
Clinicaltrials.gov identifier:
NCT04794322 (https://clinicaltrials.gov/show/NCT04794322)
Prevention
https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study
Clinicaltrials.gov identifier:
NCT02997228 (https://clinicaltrials.gov/show/NCT02997228)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation
Clinicaltrials.gov identifier:
NCT02478892 (https://clinicaltrials.gov/show/NCT02478892)
Prevention
https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations
Clinicaltrials.gov identifier:
NCT04042831 (https://clinicaltrials.gov/show/NCT04042831)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw
Clinicaltrials.gov identifier:
NCT04008030 (https://clinicaltrials.gov/show/NCT04008030)
Treatment
People with metastatic colorectal cancer that is MSI-High
https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy
Clinicaltrials.gov identifier:
NCT04666740 (https://clinicaltrials.gov/show/NCT04666740)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer
Clinicaltrials.gov identifier:
NCT00823654 (https://clinicaltrials.gov/show/NCT00823654)
Prevention
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Clinicaltrials.gov identifier:
NCT03990896 (https://clinicaltrials.gov/show/NCT03990896)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Clinicaltrials.gov identifier:
NCT04353973 (https://clinicaltrials.gov/show/NCT04353973)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/70/metastatic-prostate-cancer-project
Surveys, Registries, Interviews
https://www.facingourrisk.org/research-clinical-trials/study/60/the-metastatic-breast-cancer-project
Surveys, Registries, Interviews
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Clinicaltrials.gov identifier:
NCT03250078 (https://clinicaltrials.gov/show/NCT03250078)
Prevention
https://www.facingourrisk.org/research-clinical-trials/study/90/connect-my-variant
Surveys, Registries, Interviews
https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results
Clinicaltrials.gov identifier:
NCT02595957 (https://clinicaltrials.gov/show/NCT02595957)
Prevention
https://www.facingourrisk.org/research-clinical-trials/study/86/talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job
Clinicaltrials.gov identifier:
NCT03572374 (https://clinicaltrials.gov/show/NCT03572374)
Quality of Life
https://www.facingourrisk.org/research-clinical-trials/study/85/breast-cancer-treatment-in-women-with-palb2-mutations
Surveys, Registries, Interviews
The PALB2 Study is an international research study to better understand breast cancer treatment among women with a PALB2 gene mutation.
https://www.facingourrisk.org/research-clinical-trials/study/84/ellies-project
Quality of Life
A survey to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.
https://www.facingourrisk.org/research-clinical-trials/study/33/identification-and-analysis-of-families-with-genetic-susceptibility-to-cancer-registry
Surveys, Registries, Interviews
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.